Literature DB >> 19394651

Anti-angiogenic therapy on hepatocellular carcinoma development and progression.

Yuji Ishii1, Taro Sakamoto, Rysuke Ito, Katsuhiko Yanaga.   

Abstract

BACKGROUND: The hypervascular nature of hepatocellular carcinoma (HCC) has led a number of investigators to explore the potential of anti-angiogenic therapy for this cancer. We aimed to investigate the efficacy of anti-angiogenetic therapy for the prevention and treatment of HCC.
METHODS: An experimental model of HCC induced by diethylnitrosamine (DEN) was used in this study as a model resembling human HCC. Because endothelial cells play a central role in angiogenesis, FR-118487 (FR) with a direct effect on endothelial cells was selected for use in this study. FR-treated rats were divided into three groups of five animals each according to the timing of FR treatment, i.e., at the initiation of exposure to DEN (group I), after 6 wk of DEN exposure (group II), and after 12 wk of DEN exposure (group III).
RESULTS: No macroscopic nodules were observed in group I. Moreover, no significant difference in the mean maximum diameter and number of HCC nodules were found between the control group at 12 wk and group III at 18 wk. Thus, FR was shown to have a chemopreventive effect in addition to causing dormancy of HCC. The results obtained, including IL-8 levels, reflected the effect on HCC of anti-angiogenic therapy with FR.
CONCLUSION: Anti-angiogenic therapy may be effective for both chemoprevention and tumor dormancy in HCC associated with chronic liver disease. IL-8 may be useful as a marker of the efficacy of anti-angiogenic therapy for HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19394651     DOI: 10.1016/j.jss.2008.09.015

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

Review 1.  The prevention of infection-associated cancers.

Authors:  Silvio De Flora; Paolo Bonanni
Journal:  Carcinogenesis       Date:  2011-03-24       Impact factor: 4.944

2.  Enhanced antitumor efficacy by combination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate-based vaccine.

Authors:  Maolei Xu; Ling Zhou; Peng Zhang; Yong Lu; Chiyu Ge; Wenjun Yao; Yun Xing; Wen Xiao; Yuankai Dong; Jie Wu; Rongyue Cao; Taiming Li
Journal:  Tumour Biol       Date:  2013-06-15

3.  Characterizing venous vasculatures of hepatocellular carcinoma using a multi-breath-hold two-dimensional susceptibility weighted imaging.

Authors:  Shi-Xin Chang; Guan-Wu Li; Yao Chen; Hong Bao; Lei Zhou; Jun Yuan; Dong-Mei Wu; Yong-Ming Dai
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

Review 4.  Epidemiology of cancers of infectious origin and prevention strategies.

Authors:  S De Flora; S La Maestra
Journal:  J Prev Med Hyg       Date:  2015-06-10

5.  In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model.

Authors:  Chunfeng Si; Maolei Xu; Meiyu Lu; Yan Yu; Meizi Yang; Miaomiao Yan; Ling Zhou; Xiaoping Yang
Journal:  Oncol Lett       Date:  2017-10-11       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.